| 臺大學術典藏 |
2022-09-14T01:29:27Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; CHIEN-HUNG CHEN; Hsu C.-S.; Hui Y.T.; Li M.K.K.; Liu C.-H.; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2022-09-09T04:21:24Z |
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
|
Park J.; Le A.K.; Tseng T.-C.; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2022-02-23T02:12:22Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; CHIEN-HUNG CHEN; Hsu C.-S.; Hui Y.T.; Li M.K.K.; Liu C.-H.; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu Y.-C.; Yeh M.-L.; Wong G.L.-H.; CHIEN-HUNG CHEN; Peng C.-Y.; Buti M.; Enomoto M.; Xie Q.; Trinh H.; Preda C.; Liu L.; Cheung K.-S.; Yeo Y.H.; Hoang J.; Huang C.-F.; Riveiro-Barciela M.; Kozuka R.; Istratescu D.; Tsai P.-C.; Accarino E.V.; Lee D.-H.; Wu J.-L.; Huang J.F.; Dai C.-Y.; Cheung R.; Chuang W.-L.; Yuen M.-F.; Wong V.W.-S.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; CHIEN-HUNG CHEN; Hsu C.-S.; Hui Y.T.; Li M.K.K.; Liu C.-H.; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu Y.-C.; Yeh M.-L.; Wong G.L.-H.; CHIEN-HUNG CHEN; Peng C.-Y.; Buti M.; Enomoto M.; Xie Q.; Trinh H.; Preda C.; Liu L.; Cheung K.-S.; Yeo Y.H.; Hoang J.; Huang C.-F.; Riveiro-Barciela M.; Kozuka R.; Istratescu D.; Tsai P.-C.; Accarino E.V.; Lee D.-H.; Wu J.-L.; Huang J.F.; Dai C.-Y.; Cheung R.; Chuang W.-L.; Yuen M.-F.; Wong V.W.-S.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2022-01-24T09:31:44Z |
Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study
|
Dai C.-Y.; Tseng T.-C.; Wong G.L.H.; Huang J-F.; Wong V.W.S.; CHUN-JEN LIU; Yu M.-L.; Chuang W.-L.; Kao J.-H.; Yuen Chan H.L.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:22Z |
Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
|
Wong V.W.-S.; Chan W.-K.; Chitturi S.; Chawla Y.; Dan Y.Y.; Duseja A.; Fan J.; Goh K.-L.; Hamaguchi M.; Hashimoto E.; Kim S.U.; Lesmana L.A.; Lin Y.-C.; CHUN-JEN LIU; Ni Y.-H.; Sollano J.; Wong S.K.-H.; Wong G.L.-H.; Chan H.L.-Y.; Farrell G. |
| 臺大學術典藏 |
2022-01-24T09:31:22Z |
The Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups
|
Chitturi S.; Wong V.W.-S.; Chan W.-K.; Wong G.L.-H.; Wong S.K.-H.; Sollano J.; Ni Y.-H.; CHUN-JEN LIU; Lin Y.-C.; Lesmana L.A.; Kim S.U.; Hashimoto E.; Hamaguchi M.; Goh K.-L.; Fan J.; Duseja A.; Dan Y.Y.; Chawla Y.; Farrell G.; Chan H.L.-Y. |
| 臺大學術典藏 |
2021-09-04T06:12:16Z |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
|
Lui Y.Y.-N.; Tsoi K.K.-F.; Wong V.W.-S.; JIA-HORNG KAO; Hou J.-L.; Teo E.-K.; Mohamed R.; Piratvisuth T.; Han K.-H.; Mihm U.; Wong G.L.-H.; Chan H.L.-Y. |
| 臺大學術典藏 |
2021-09-04T06:11:45Z |
Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study
|
Dai C.-Y.; Tseng T.-C.; Wong G.L.H.; Huang J-F.; Wong V.W.S.; Liu C.-J.; Yu M.-L.; Chuang W.-L.; JIA-HORNG KAO; Yuen Chan H.L.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T05:16:39Z |
Modelling NAFLD disease burden in four Asian regions—2019-2030
|
Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. |
| 臺大學術典藏 |
2021-09-04T05:16:35Z |
Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply
|
Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. |
| 臺大學術典藏 |
2021-09-04T05:16:20Z |
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
|
Liu M.; Tseng T.-C.; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-05-24T07:20:16Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; Chen C.-H.; Hsu C.-S.; Hui Y.T.; Li M.K.K.; CHEN-HUA LIU; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2021-02-02T02:20:54Z |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
|
Hsu Y.-C.; Yip T.C.-F.; Ho H.J.; Wong V.W.-S.; Huang Y.-T.; El-Serag H.B.; Lee T.-Y.; MING-SHIANG WU; Lin J.-T.; Wong G.L.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:47Z |
Corrigendum to “Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B” [J Hepatol 69 (2018) 278–285](S0168827818301703)(10.1016/j.jhep.2018.02.032)
|
Hsu Y.-C.; Yip T.C.-F.; Ho H.J.; Wong V.W.-S.; Huang Y.-T.; El-Serag H.B.; Lee T.-Y.; MING-SHIANG WU; Lin J.-T.; Wong G.L.-H.; Wu C.-Y. |
| 國立成功大學 |
2021 |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu, Y.-C.;Yeh, M.-L.;Wong, G.L.-H.;Chen, Chen C.-H.;Peng, C.-Y.;Buti, M.;Enomoto, M.;Xie, Q.;Trinh, H.;Preda, C.;Liu, Liu L.;Cheung, K.-S.;Yeo, Yeo Y.H.;Hoang, J.;Huang, C.-F.;Riveiro-Barciela, M.;Kozuka, R.;Istratescu, D.;Tsai, P.-C.;Accarino, E.V.;Lee, D.-H.;Wu, J.-L.;Huang, J.F.;Dai, C.-Y.;Cheung, R.;Chuang, W.-L.;Yuen, M.-F.;Wong, V.W.-S.;Yu, M.-L.;Nguyen, M.H. |
| 臺大學術典藏 |
2020-12-28T08:14:12Z |
Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
|
Farrell G.; Chan H.L.-Y.; Wong G.L.-H.; Wong S.K.-H.; Lin Y.-C.; Liu C.-J.; YEN-HSUAN NI; Sollano J.; Wong V.W.-S.;Chan W.-K.;Chitturi S.;Chawla Y.;Dan Y.Y.;Duseja A.;Fan J.;Goh K.-L.;Hamaguchi M.;Hashimoto E.;Kim S.U.;Lesmana L.A.;Lin Y.-C.;Liu C.-J.;Yen-Hsuan Ni;Sollano J.;Wong S.K.-H.;Wong G.L.-H.;Chan H.L.-Y.;Farrell G.; Wong V.W.-S.; Chan W.-K.; Chitturi S.; Chawla Y.; Dan Y.Y.; Duseja A.; Fan J.; Goh K.-L.; Hamaguchi M.; Hashimoto E.; Kim S.U.; Lesmana L.A. |
| 臺大學術典藏 |
2020-12-28T08:14:12Z |
The Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups
|
Chan H.L.-Y.; Farrell G.; Chawla Y.; Dan Y.Y.; Duseja A.; Fan J.; Goh K.-L.; Hamaguchi M.; Hashimoto E.; Kim S.U.; Lesmana L.A.; Lin Y.-C.; Liu C.-J.; Chitturi S.; Wong V.W.-S.; Chan W.-K.; Wong G.L.-H.; Wong S.K.-H.; Sollano J.; YEN-HSUAN NI; Chitturi S.;Wong V.W.-S.;Chan W.-K.;Wong G.L.-H.;Wong S.K.-H.;Sollano J.;Yen-Hsuan Ni;Liu C.-J.;Lin Y.-C.;Lesmana L.A.;Kim S.U.;Hashimoto E.;Hamaguchi M.;Goh K.-L.;Fan J.;Duseja A.;Dan Y.Y.;Chawla Y.;Farrell G.;Chan H.L.-Y. |
| 臺大學術典藏 |
2020-11-03T08:19:39Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; Chen C.-H.; Hsu C.-S.; Hui Y.T.; Li M.K.K.; CHEN-HUA LIU; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2020-11-02T02:04:07Z |
Corrigendum to ��Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B�� [J Hepatol 69 (2018) 278�V285](S0168827818301703)(10.1016/j.jhep.2018.02.032)
|
Hsu Y.-C.; Wu C.-Y.; Wong G.L.-H.; Lin J.-T.; MING-SHIANG WU; Lee T.-Y.; El-Serag H.B.; Huang Y.-T.; Wong V.W.-S.; Yip T.C.-F.; Ho H.J. |
| 臺大學術典藏 |
2018-09-10T08:16:48Z |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
|
Lui, Y.Y.-N.;Tsoi, K.K.-F.;Wong, V.W.-S.;Kao, J.-H.;Hou, J.-L.;Teo, E.-K.;Mohamed, R.;Piratvisuth, T.;Han, K.-H.;Mihm, U.;Wong, G.L.-H.;Chan, H.L.-Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018 |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
|
Hsu Y.-C.; Yip T.C.-F.; Ho H.J.; Wong V.W.-S.; Huang Y.-T.; El-Serag H.B.; Lee T.-Y.; MING-SHIANG WU; Lin J.-T.; Wong G.L.-H.; Wu C.-Y. |
